Finding the right balance between efficacy and tolerability for TB treatment.

Haas, M K; Ignatius, E H; Stout, J E; Dooley, K E

Haas, M K; Ignatius, E H; Stout, J E; Dooley, K E.

Afiliação

Haas MK; Denver Metro Tuberculosis Program, Denver Public Health, Denver, CO, USA, Division of Infectious Diseases, Department of Medicine, University of Colorado-Denver Anschutz Medical Campus, Aurora, CO, USA.
Ignatius EH; Divisions of Clinical Pharmacology & Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Stout JE; Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC, USA, <email></email>, Email: michelle.haas@dhha.org.
Dooley KE; Divisions of Clinical Pharmacology & Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Int J Tuberc Lung Dis ; 24(11): 1225b-1226, 2020 11 01.

Article em En | MEDLINE | ID: mdl-33172541

Assuntos

Tuberculose Resistente a Múltiplos Medicamentos; Tuberculose; Humanos; Rifampina; Tuberculose/tratamento farmacológico; Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Tuberculose Resistente a Múltiplos Medicamentos Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Int J Tuberc Lung Dis Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google